Press releases

7 March, 2019

Regulatory

NeuroVive receives SEK 28.2 Million in a directed new share issue

Lund, Sweden, 7 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has successfully conducted a directed new issue of shares, which has rais ...

28 February, 2019

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2018

Positioned for clinical progress

28 February, 2019

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 71,661,048 as a result ...

21 February, 2019

NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds

Lund, Sweden, 21 February 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of ...

11 February, 2019

Regulatory

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares ...

25 January, 2019

Regulatory

NeuroVive’s Board Members, Senior Executives and employees have subscribed to shares in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 1,778,995 shares equivalent to MSEK 2.4 which exceeds current holdings.

22 January, 201919 February, 2024

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

Lund, Sweden, 22 January 2019 – NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB’s (publ) (“N ...

18 January, 2019

NeuroVive – company presentations January 2019

Lund, Sweden, 18 January 2019 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX:NEVPF) informs on its scheduled company presentation for January 2019.

17 January, 2019

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 January 2019, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. All resolutions were unani ...

28 December, 2018

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 December 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 126,235 as a result of ...

11 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 1 pm on Thursday 17 January 2019 at Medicon Village, Scheelevägen ...

11 December, 2018

Regulatory

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018: